PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: SmallCapReview

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SmallCapReview Initiates Coverage of Echo Therapeutics - a leading site for news and information on small caps and penny stocks is adding Echo Therapeutics (ECTE) to its list of stocks
SmallCapReview Initiates Coverage of Echo Therapeutics


NewswireToday - /newswire/ - Winston-Salem, NC, United States, 2010/01/16 - a leading site for news and information on small caps and penny stocks is adding Echo Therapeutics (ECTE) to its list of stocks "On the Radar".

Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage/Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Echo Therapeutics (ECTE) is a company developing a non-invasive (needle-free), wireless, system for people with diabetes and for use in hospital critical care units.

ECTE's products include the transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery. The Prelude™ SkinPrep System incorporates Echo's patented feedback mechanism for optimal, safe control of skin ablation and its non-invasive transdermal biosensor technologies. With Symphony, Echo is focused on providing reliable, on-demand glucose data continuously, conveniently and cost-effectively. Echo's goal is to change the current paradigm of invasive, episodic glucose testing for people with diabetes and for use in hospital critical care settings with a reliable, needle-free and easy-to-use tCGM system that can provide continuous tracking and trending of glucose levels throughout the day and night.

ECTE is leveraging it's AzoneTS™ skin ablation technology to develop a wide-variety of new transdermal reformulations of pharmaceutical products previously approved by the FDA. Echo has submitted a New Drug Application (NDA) to the FDA covering its lead AzoneTS-reformulated product candidate, Durhalieve™, for treatment of corticosteroid responsive dermatoses.

Echo is also focused on Phase 2 development of Durhalieve for keloid scarring.

What does all that mean in English? It means this: ECTE has a revolutionary, PATENTED, one-of-a-kind diabetes monitoring system that uses a proprietary needle-free platform technology! In short, if your child, friend, family member or anyone one of 171 million people with diabetes according to The World Health Organization, a figure that is likely to more than double by 2030 then they no longer require a needle every single day. ECTE's technology is quickly making inroads in the medical community as a viable alternative to needles and could easily become an acquisition target!

ECTE also believes that its Prelude SkinPrep System will allow many drugs currently delivered by needle injection to be administered without a needle by using Prelude prior to transdermal drug administration, this alone could add substantial value to ECTE.

ECTE Investor Highlights

Entered into a $15 million license agreement with Ferndale Pharma Group, Inc. which granted to Ferndale the right to develop, market and sell Echo's Prelude SkinPrep System for enhanced delivery of Ferndale's topical lidocaine product, LMX4, in North America and the United Kingdom. In exchange, Echo received: An initial licensing fee of $750,000 and an additional $750,000 fee upon FDA approval; $12.5 million in milestones and guaranteed minimum royalty payments; and Royalties on net sales of disposable Prelude components.

Echo anticipates that no further changes will be made to the Prelude SkinPrep System and that the current device will be the one used for sale, subject to FDA market clearance of the product. The final Prelude device replaces the prototype device used in earlier clinical trials and will be tested in the near-term in a study using LMX4 lidocaine cream which should form the basis for a 510-k filing with Ferndale Pharma Group for the enhanced delivery of lidocaine. The Company believes that the addressable market for enhanced, fast acting topical lidocaine exceeds $1 billion.

Entered into a license agreement with Handok Pharmaceuticals Co., Ltd. which granted Handok a license to develop, market and sell Echo's Symphony tCGM System for needle-free continuous glucose monitoring in South Korea. In exchange, Echo received: A licensing fee of approximately $600,000 upon execution of the License Agreement; Milestone payments upon receipt of the US FDA's clearance of Symphony and upon the first commercial sale of Symphony in South Korea; Royalties on net sales of Symphony; and Additional milestone payments upon the achievement of other commercial targets.

In November, Echo announced positive results of a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 Diabetes. The purpose of the study was to test the performance of the new, improved one-piece, cost-effective and easy-to-use biosensor. To date, Echo has conducted six consecutive positive pilot studies demonstrating effective and safe monitoring of glucose levels using Echo's skin permeation platform technology.

To date, Echo's medical device patent portfolio consists of 7 U.S. patents and 4 foreign patents, as well as 8 U.S. patent applications and 37 foreign patent applications.

During 2009, Echo either converted or repaid approximately $2.4 million of secured and unsecured debt, improving its working capital position.

ECTE anticipates Achieving AMEX or Nasdaq listing and completing additional strategic partner licensing arrangements.

"The last year was one of significant accomplishment and progress against the backdrop of a very tough macroeconomic climate. Through much hard work, we believe that we have set the stage for an exciting and productive 2010," CEO Dr. Mooney stated. "Looking forward, royalties on Prelude disposables and lidocaine sales provide near-term revenue opportunity for Echo. Additionally, we are positioned to be 'first-to-market' with tCGM in the hospital critical care market and we estimate that the hospital market opportunity for continuous glucose monitoring is greater than $1 billion. In addition, we plan to develop the Symphony product for use in the consumer market, providing additional upside potential and partnership possibilities in this more than $10 billion market opportunity."

Features available at include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.

No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. has been compensated up three thousand five hundred dollars by a third party Green Horseshoe for its services with regards to Echo Therapeutics.

Copyright SmallCapReview. is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play.

Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage/Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: SmallCapReview


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #
  Your Banner Ad showing on ALL
Brokerage/Trading articles,
CATCH Visitors via Your Competitors Announcements!

SmallCapReview Initiates Coverage of Echo Therapeutics

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Thomas Englebert - 
336-838-5005 editor[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SmallCapReview securities in any jurisdiction including any other companies listed or named in this release.

Brokerage/Trading via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From SmallCapReview / Company Profile

Read Brokerage/Trading Most Recent Related Newswires:

SRMEX's Vice Chairman Eikichi Hirano About the Gradual Expansion of Capital Market
Xtrade Wins Best Broker in the Middle East Award
Russian Foreign Trade Reports on Russian Trade with North American Countries Q1 2016
DarkMaindFX Introduces the Beta Version of its Economic Indicator Services
Hermes International Expo to Celebrate 25th Anniversary in Delaware County
GoldSilver Central Approved As Singapore Bullion Market Association Member
OANDA Acquires Tradestation Forex Accounts
[TYPO FOUND BY SYSTEM] Beeline Broking Ltd Launches 'Tailor Made Brokerage Plan' Announces Key Features - Makes it the Best Binary Options Signals Service
Binary Options Signals from Helps Traders to Get Higher Win-Rate
/RC/ Van Ecker Couder Associates Announce Expansion Program
/RC/ Voth Nixon Group Bolsters Deferred Income Annuity
Grant Becker Associates Chalks Up Another Successful Year of CSR Activities
Evanson Asset Management Dividend Stocks to Safeguard An All-weather Portfolio
AKFinancials Announces its 2015 Forex Course Schedule

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  Intrinsic Executive Search Ltd

Visit  La Bella Bakery Artisan Bakery Arizona

  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (